XYF19 CAR-T Cell Therapy

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameXYF19 CAR-T Cell Therapy
Drug Alias NameXYF-19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-CD19Mitogen-activated protein kinase kinase kinase kinase 1 modulators
TargetsB-lymphocyte antigen CD19Mitogen-activated protein kinase kinase kinase kinase 1
Therapy Area/IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Yinming Biomedical Technology Co LtdXi'An Yufan Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXi'An Yufan Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A